February 7, 2012
Clinical Results from Aduro’s Phase 1 Trials Published in
Clinical Cancer Research. Read it
here.
November 10, 2011
Aduro BioTech patent upheld by USPTO. Read it
here.
October 11, 2011
Aduro BioTech announces first patient treated in Phase 2 pancreatic cancer trial. Read it
here.
September 22, 2011
Aduro BioTech, Inc. appoints Thomas Dubensky, Jr. as Chief Scientific Officer. Read it
here.
September 13, 2011
Aduro BioTech, Inc. Announces Three Grants. Read it
here.
April 20, 2011
Aduro BioTech completes $19.25 million Series B financing. Read it
here.
April 18, 2011
Aduro BioTech licenses GVAX Pancreas from BioSante Pharmaceuticals. Read it
here.
December 7, 2010
Aduro BioTech announces first presentation of clinical results from CRS-207 Phase 1 trial. Read it
here.
November 29, 2010
Aduro BioTech receives "Outstanding Scientific Achievement" award for biodefense program. Read it
here.
November 3, 2010
Aduro BioTech awarded $442,000 under U.S. Qualified Therapeutic Discovery Project Program. Read it
here.
August 16, 2010
See the article on Aduro from the San Francisco Business Times
July 15, 2010
Aduro BioTech announces key milestones in advancing its leading
Listeria-based immunotherapy program. Read it
here.
November 12, 2009
See BioWorld's article on Aduro
November 10, 2009
Aduro completes Series A-1 Financing
November 9, 2009
KTVU explores Aduro’s promising research
September 14, 2009
View TIME Magazine's article "A Shot at Cancer" on using vaccines to treat cancer
September 10, 2009
Aduro Biotech's Thermotherapy technology has been spun out to Aspen Medisys, Inc.